Drug Profile

EI 011

Alternative Names: EI-011

Latest Information Update: 01 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Elixiron Immunotherapeutics
Class Antibodies; Antineoplastics; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

01 Sep 2021 Pharmacodynamics data from a preclinical trials in Breast Cancer released by Elixiron Immunotherapeutics (Elixiron Immunotherapeutics pipeline, August 2021)
18 Aug 2021 Early research in Breast cancer in China (Parenteral) (Elixiron Immunotherapeutics pipeline, August 2021)
18 Aug 2021 Early research in Cancer in China (Parenteral) (Elixiron Immunotherapeutics website, August 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com